Bimosiamose has anti-inflammatory effects[1]. Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, L-selectin, and P-selectin respectively.

Bimosiamose (TBC-1269) inhibits cell recruitment. And it does not possess any cytotoxic effect on neutrophils. Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment.

Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved[1]. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion. It also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion.

187269-40-5

C46H54O16

862.91

TBC-1269

DMSO:125 mg/mL (144.86 mM),Need ultrasonic
0.1 M NaOH:25 mg/mL (28.97 mM),ultrasonic and adjust pH to 10 with NaOH
Powder: -20°C for 3 years
In solvent: -80°C for 2 years